Date:5/15/2009

Therapeutics Location: Level 4, Valencia Room, W415A -- Phase II results of Study PX-171-007: A Phase Ib/II study of carfilzomib (CFZ), a selective proteasome inhibitor, in patients with selected advanced metastatic solid tumors. (Abstract #3515) Monday, June 1, 2009 at 3:45 p.m. ET Track: Developmental Therapeutics, Lymphoma and Plasma Cell Disorders Session: New Agents for Multiple Myeloma Location: Level 2, West Hall F1 -- Final results of PX-171-003-A0, part 1 of an open-label, single- arm, Phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM). (Abstract #8504) Poster Presentations Monday, June 1, 2009 from 2:00 p.m. to 6:00 p.m. ET Track: Lymphoma and Plasma Cell Disorders Session: Lymphoma and Plasma Cell Disorders Location: Level 2, W240A -- PX-171-004, a multicenter Phase II study of carfilzomib (CFZ) in patients with relapsed myeloma: An efficacy update. (Abstract #8537) -- PX-171-006: Phase Ib multicenter dose escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) and low-dose dexamethasone (loDex) in relapsed and refractory multiple myeloma (MM): Preliminary results. (Abstract #8541)

About Carfilzomib

Carfilzomib is the first in a new class of selective, irreversible proteasome inhibitors. Carfilzomib produces specific and sustained inhibition of the proteasome, leading to apoptosis in cancer cells with minimal off-target effects. In Phase 1 and Phase 2 clinical trials, carfilzomib has demonstrated single-agent activity in hematologic malignancies and solid tumors, including multiple myeloma, Waldenstrom's macroglobulinemia, mantle cell lymphoma, and renal cell carcinoma.

Proteolix is conducting a
'/>"/>

SOURCE Proteolix, Inc. Copyright©2009 PR Newswire. All rights reserved

4 GOOD

Page: 1 2 3
Related biology technology :

1. Proteolix Announces New Appointment in Finance and Expands Clinical and Regulatory Leadership Team
2. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
3. Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
4. Proteolix Raises $79 Million in Series C Financing
5. Proteolixs Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. China Biologic Products to Present at CCG IRs China Rising Conference and Oppenheimers China Dragon Call Conference in New York
8. EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting
9. Oncolytics Biotech(R) Inc.s Research Collaborators to Present Data on REOLYSIN(R) Clinical Trials at ASCO Conference
10. Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting
11. Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting